Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/09/2021
• Auteurs : Dérioz PierreLaurent ArcusetPhilippe BachimonYves HascoëtMaud LoireauPhilippe Béringuier
• Organismes : UMR 228 Espace-Dev, Espace pour le développement Université d'Avignon Université d'Avignon UMR 228 Espace-Dev, Espace pour le développement Institut de Recherche pour le Développement (IRD en Occitanie) Université de Perpignan Via Domitia Géographie de l'environnement

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Joanna KedraRaphaele SerorPhilippe DieudéArnaud ConstantinEric ToussirotElias KfouryCharles MassonDivi Yk CornecJean Jacques DubostLaurent MarguerieSebastien OttavianiFranck GradosRakiba BelkhirOlivier FainPhilippe GoupilleChristelle SordetBruno FautrelPeggy PhilippeMuriel PipernoBernard CombeOlivier LambotteChristophe RichezJérémie SellamThomas SenéGuillaume DenisThierry LequerreThierry LazureXavier MarietteGaetane Nocturne
• Organismes : Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre de Physiopathologie Toulouse Purpan Centre de Rhumatologie [CHU Toulouse] Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier de Brive-la-Gaillarde Centre Hospitalier Universitaire d'Angers CHRU Brest - Service de Rhumatologie CHU Clermont-Ferrand Institut Calot [Fondation Hopale] AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Amiens-Picardie Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU Saint-Antoine [AP-HP] CHU Trousseau [APHP] Centre Hospitalier Universitaire [Strasbourg] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Lyon Sud [CHU - HCL] Centre Hospitalier Régional Universitaire [Montpellier] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] CHU de Bordeaux Pellegrin [Bordeaux] Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier de Rochefort Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes CHU Rouen Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
• Publié dans RMD Open : Rheumatic & Musculoskeletal Diseases le 21/10/2020

---

Résumé : Objectives To study the characteristics of B-cell non-Hodgkin’s lymphoma (NHL) or Hodgkin lymphoma complicating rheumatoid arthritis (RA) and to identify RA-related factors associated with their occurrence. Methods A multicentre case–control study was performed in France. Cases were patients with RA fulfilling ACR-EULAR 2010 criteria in whom B-cell NHL or Hodgkin lymphoma developed after the diagnosis of RA. For each case, 2 controls were assigned at random from the ESPOIR cohort and were matched on age at lymphoma diagnosis (cases)/age at the 10-year follow-up visit in the cohort (controls). Case and control characteristics were compared to identify parameters associated with the occurrence of lymphoma. Results 54 cases were included and matched to 108 controls. Lymphomas were mostly diffuse large B-cell lymphoma (DLBCL, n=27, 50.0%). On immunochemistry, 4 of 27 (14.8%) lymphoma cases were positive for Epstein-Barr virus. On univariate analysis, factors associated with the occurrence of lymphoma were male sex (OR 3.3, 95% CI 1.7 to 6.7), positivity for ACPA (OR 5.1, 95% CI 2.0 to 15.7) and rheumatoid factor (OR 3.9, 95% CI 1.6 to 12.2), and erosions on radiographs (OR 3.8, 95% CI 1.7 to 8.3) and DAS28 (OR 2.0, 95% CI 1.5 to 2.7), both at the time of matching. Methotrexate, TNF blockers and a number of previous biologics were not associated with the occurrence of lymphoma. On multivariable analysis, erosions and DAS28 remained significantly associated with increased risk of lymphoma. Conclusion Lymphomas complicating RA are mostly DLBCL. Risk of lymphoma in patients with RA was increased with markers of disease activity and severity, which supports the paradigm of a continuum between autoimmunity and lymphomagenesis in RA.

---

Fichiers liés : e001698.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Sophie MartinCharlotte KaeufferPierre LeyendeckerNicolas TuzinYoussef TaziFrédérique Schaff-WendlingTiffanie KleinhenyStéphanie Husson-WetzelGuillaume PamartJean-Marc LimacherOlivier ClercElise DicopJean-Emmanuel KurtzPhilippe BarthélémyJustine Gantzer
• Organismes : Institut de Cancérologie de Strasbourg Europe Hôpitaux Universitaires de Strasbourg Service de radiologie [Strasbourg] Laboratoire d'Épidémiologie et de Santé Publique [Strasbourg] Clinique Sainte Anne [Strasbourg] Clinique de l'Orangerie [Strasbourg] Groupe hospitalier de la région de Mulhouse et Sud-Alsace Groupe hospitalier de la région de Mulhouse et Sud-Alsace Service de chirurgie thoracique [Strasbourg] Hôpital Louis Pasteur [Colmar] Maison de Santé Béthel [Oberhausbergen] Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe Institut de Cancérologie de Strasbourg Europe
• Publié dans Oncologist le 26/10/2020

---

Résumé : Abstract We describe a large series of patients with solid tumors in an early COVID-19 cluster in the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 patients with cancer under treatment or on follow-up for any type of malignant solid tumor and positive for SARS-CoV-2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified as a subset of more vulnerable patients; immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic. Implications for Practice This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. This study identified patients with gastrointestinal cancers as a more vulnerable subset of patients with cancer and found that immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis to be risk factors for death. The reported data indicate the necessity of weighing the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies in any future wave of COVID-19.

---

Source

---

• Type de publi. :
• Date de publi. : 01/09/2021
• Auteurs : Daria Kartasheva-EbertzJesintha GastonPierre-Philippe MassaultOlivier ScattonSebastien GaujouxJean-Christophe VaillantStanislas PolSylvie Lagaye
• Organismes : Immunobiologie des Cellules dendritiques Université Paris Cité Hôpital Cochin [AP-HP] Université Paris Cité CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Service d'hépatologie médicale [CHU Cochin] Université Paris Cité Immunobiologie des Cellules dendritiques

---

Résumé : Il‐17A is considered to guide liver inflammation and fibrosis. Using human liver slice culture, we aim to study whether IL‐17A is capable of influencing the fibrogenesis, but also, to look into lymphatic immune cell composition, secreting IL‐17A. Using human liver samples (F0‐F4) and blood samples, collected after partial hepatectomy due to different pathologies, we analyzed IL‐17A secretion and immune cell profile. Liver tissue was used for primary culture of human liver slices, followed by subsequent cytokine stimulation and analysis by Elisa of fibrotic markers. The Huh7.5.1 cell line was used for SeaHorse and WB analysis. IL‐17A concentration in human liver tissue was significantly higher in the early fibrotic stage compared with the advanced stage. Th17 T cells and, to a lesser extent, MAIT cells are the main sources of IL‐17A in both compartments, liver and blood. Moreover, the presence of liver Th17IL‐ 17A+INFγ+ cells were detected. IL‐17A stimulation of human liver slices increases the expression of profibrotic markers. Stimulation by IL‐17A+TGF‐β1 removes the reserve respiratory capacity in Huh7.5.1 cells, while RA addition is capable to restore it and to reverse the expression of LC3II/LC3I ratio. IL‐17A, secreted by Th17 and MAIT cells, induce the expression of pro‐fibrotic markers. However, the level of hepatic IL‐17A secretion is probably more related to the underlying pathologies that cause fibrosis rather than to the mechanism of fibrosis itself. There is also a terrain of communication between IL‐17A and retinoic acid in the liver, that should be investigated.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Stéphanie LejeuneRony SfeirVéronique RousseauArnaud BonnardThomas GelasMadeleine AumarNicoleta PanaitPierre-Yves RabattuSabine IrtanVirginie FouquetAurélie Le MandatStephan de Napoli CocciEdouard HabonimanaThierry LamireauJean-Louis LemelleFrédéric ElbazIsabelle TalonNadia BoudaoudHossein AllalPhilippe BuissonThierry PetitEmmanuel SapinHubert LardyFrançoise SchmittGuillaume LevardAurélien ScalabreJean-Luc MichelOlivier JabyCécile PelatanPhiline de VriesCorinne BorderonLaurent FourcadeJean BreaudMyriam ArnouldCécilia TolgYann ChaussyStephan GeissChristophe LaplaceElodie DrumezSawsan El MouradCaroline ThumerelleFrédéric Gottrand
• Organismes : Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286 Centre de référence des affections congénitales et malformatives de l'oesophage Hôpital Necker - Enfants Malades [AP-HP] AP-HP Hôpital universitaire Robert-Debré [Paris] Hospices Civils de Lyon Institute for Translational Research in Inflammation - U 1286 Centre de référence des affections congénitales et malformatives de l'oesophage CHU Marseille Service de chirurgie pédiatrique [CHU Grenoble] CHU Trousseau [APHP] Centre de Recherche Saint-Antoine Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Bordeaux population health Centre Hospitalier Régional Universitaire de Nancy CHU Rouen Biomatériaux et Bioingénierie Hôpitaux Universitaires de Strasbourg Hôpital universitaire Robert Debré [Reims] Département Chirurgie Pédiatrique [CHRU Montpellier] CHU Amiens-Picardie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire d'Angers Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Service de Chirurgie pédiatrique [CHU Saint-Etienne] Santé Ingénierie Biologie Saint-Etienne Centre Hospitalier Universitaire de La Réunion Centre Hospitalier Intercommunal de Créteil Centre Hospitalier Le Mans (CH Le Mans) Centre Hospitalier Régional Universitaire de Brest CHU Clermont-Ferrand Hôpital Dupuytren [CHU Limoges] Centre Hospitalier Universitaire de Nice Centre Hospitalier Regional d'Orléans Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Centre Hospitalier Régional Universitaire de Besançon Hôpitaux Civils de Colmar CHU Pointe-à-Pitre / Abymes [Guadeloupe] Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Service de Biostatistiques [CHRU Lille] Institute for Translational Research in Inflammation - U 1286 Groupe Hospitalier Artois-Ternois Centre Hospitalier d’Arras Institute for Translational Research in Inflammation - U 1286 Institute for Translational Research in Inflammation - U 1286
• Publié dans Pediatrics le 02/11/2020

---

Résumé : BACKGROUND AND OBJECTIVES Respiratory diseases are common in children with esophageal atresia (EA), leading to increased morbidity and mortality in the first year. The primary study objective was to identify the factors associated with readmissions for respiratory causes in the first year in EA children. METHODS A population-based study. We included all children born between 2008 and 2016 with available data and analyzed factors at birth and 1 year follow-up. Factors with a P value <.10 in univariate analyses were retained in logistic regression models. RESULTS Among 1460 patients born with EA, 97 (7%) were deceased before the age of 1 year, and follow-up data were available for 1287 patients, who constituted our study population. EAs were Ladd classification type III or IV in 89%, preterm birth was observed in 38%, and associated malformations were observed in 52%. Collectively, 61% were readmitted after initial discharge in the first year, 31% for a respiratory cause. Among these, respiratory infections occurred in 64%, and 35% received a respiratory treatment. In logistic regression models, factors associated with readmission for a respiratory cause were recurrence of tracheoesophageal fistula, aortopexy, antireflux surgery, and tube feeding; factors associated with respiratory treatment were male sex and laryngeal cleft. CONCLUSIONS Respiratory morbidity in the first year after EA repair is frequent, accounting for >50% of readmissions. Identifying high risk groups of EA patients (ie, those with chronic aspiration, anomalies of the respiratory tract, and need for tube feeding) may guide follow-up strategies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Bruno FrançoisHasan JafriJean ChastreMiguel Sánchez-GarcíaPhilippe EggimannPierre-François DequinVincent HuberlantLucia Viña SoriaThierry BoulainCédric BretonnièreJérôme PuginJosep TrenadoAna Catalina Hernandez PadillaOmar AliKathryn ShoemakerPin RenFrank CoenjaertsAlexey RuzinOlivier BarraudLeen TimbermontChristine LammensVadryn PierreYuling WuJulie VignaudSusan ColbertTerramika BellamyMark EsserFilip DubovskyMarc BontenHerman GoossensPierre-François LaterreDidier ChochradAlain DiveFrédéric ForetMarc SimonHerbert SpapenJacques CreteurYves BouckaertPatrick BistonMarc BourgeoisMartin NovacekTomas VymazalPetr SvobodaJan PachlVladimir SramekMichal HanauerTomas HrubyMartin BalikTomas SuchyAlain LepapeLaurent ArgaudFrédéric DaillerArnaud DesachyChristophe GuittonAlain MercatFerhat MezianiJean-Christophe NavellouRene RobertBertrand SouweineJean-Marc TadieAdel MaamarDjillali AnnaneFabienne TamionAntoine GrosSaad NseirCarole SchwebelGilles FranconyJean-Yves LefrantFrancis SchneiderMatthias GründlingJohann MotschLorenz ReillCaroline RolfesTobias WelteOliver CornelyFrank BloosMaria DejaKatrin SchmidtFrank WapplerAndreas Meier-HellmannApostolos KomnosVasileios BekosVasilios KoulourasIoanna SoultatiGeorgios BaltopoulosGeorgios FilntisisEpaminondas ZakynthinosSpyros ZakynthinosIoannis PnevmatikosIldikó KrémerZoltán SzentkeresztyAgnes SarkanyZsuzsa MarjanekPedro MouraMaria Consuelo Pintado DelgadoJuan Carlos Montejo GonzálezPaula RamirezAntonio Torres MartiJuan Carlos ValiaJose LorenteAna Loza VazquezRaúl de Pablo SanchezDolores EscuderoRicard Ferrer RocaJean-Luc PaganiMarco Maggiorini
• Organismes : Centre d'Investigation Clinique de Limoges Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques Service de Réanimation Polyvalente [CHU Limoges] AstraZeneca CHU Pitié-Salpêtrière [AP-HP] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Centre d’Investigation Clinique [Tours] CIC 1415 Centre d’Etude des Pathologies Respiratoires [Tours] Hospital Universitario Central de Asturias Centre Hospitalier Regional d'Orléans Hôpital Guillaume-et-René-Laennec [Saint-Herblain] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Hospital Universitario Mutua de Terrassa Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques CHU Limoges AstraZeneca AstraZeneca AstraZeneca University Medical Center [Utrecht] AstraZeneca Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques CHU Limoges Antwerp University Hospital [Edegem] Antwerp University Hospital [Edegem] AstraZeneca AstraZeneca CHU Limoges Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques AstraZeneca AstraZeneca AstraZeneca AstraZeneca Centre d'Investigation Clinique de Limoges Antwerp University Hospital [Edegem] Université Catholique de Louvain = Catholic University of Louvain
• Publié dans The Lancet Infectious Diseases le 29/10/2020

---

Résumé : Background Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. Methods We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland. Eligible patients were in the ICU, aged ≥18 years, were intubated and on mechanical ventilation, were positive for S aureus colonisation of the lower respiratory tract, as assessed by quantitative PCR (qPCR) analysis of endotracheal aspirate, and had not been diagnosed with new-onset pneumonia. Patients were excluded if they had confirmed or suspected acute ongoing staphylococcal disease; had received antibiotics for S aureus infection for more than 48 h within 72 h of randomisation; had a Clinical Pulmonary Infection Score of 6 or higher; had an acute physiology and chronic health evaluation II score of 25 or higher with a Glasgow coma scale (GCS) score of more than 5, or an acute physiology and chronic health evaluation II score of at least 30 with a GCS score of 5 or less; had a Sequential Organ Failure Assessment score of 9 or higher; or had active pulmonary disease that would impair the ability to diagnose pneumonia. Colonised patients were randomly assigned (1:1:1), by use of an interactive voice or web response system, to receive either a single intravenous infusion of suvratoxumab 2000 mg, suvratoxumab 5000 mg, or placebo. Randomisation was done in blocks of size four, stratified by country and by whether patients had received systemic antibiotics for S aureus infection. Patients, investigators, and study staff involved in the treatment or clinical evaluation of patients were masked to patient assignment. The primary efficacy endpoint was the incidence of S aureus pneumonia at 30 days, as determined by a masked independent endpoint adjudication committee, in all patients who received their assigned treatment (modified intention-to-treat [ITT] population). Primary safety endpoints were the incidence of treatment-emergent adverse events at 30 days, 90 days, and 190 days after treatment, and the incidence of treatment-emergent serious adverse events, adverse events of special interest, and new-onset chronic disease at 190 days after treatment. All primary safety endpoints were assessed in the modified ITT population. This trial is registered with ClinicalTrials.gov (NCT02296320) and the EudraCT database (2014-001097-34).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Gustave MabiamaDieudonné AdiogoPierre-Marie PreuxJean-Claude DesportPhilippe FayemendyPierre Jésus
• Organismes : Neuroépidémiologie Tropicale Epidémiologie des Maladies Chroniques en zone tropicale Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges]
• Publié dans Clinical Nutrition ESPEN le 24/10/2020

---

Résumé : Background and aims: Although the ageing of the Cameroonian population is a public health issue in the coming years, the nutritional status of the elderly is unknown. The aim of the study was to assess the nutritional status, health status and associated socio-demographic factors among elderly in Cameroon.Methods: A cross-sectional study of 599 elderly (aged 60) was conducted in urban and rural areas. Several socio-demographic, sanitary, and anthropometric (weight, height, body mass index (BMI), Waist Circumference (WC), Mid-Upper Arm Circumference (MUAC)) data were collected. Nutritional status was defined according to WHO. Multinomial analysis was performed to identify factors associated with nutritional status. The threshold of statistical significance was 5%.Results: The population, representative of the elderly, was aged 68.9 ± 7.2 years, with sex ratio M/F ¼ 0.93, weight 68.5 ± 14.7 kg, BMI 24.7 ± 5.3,WC 90.1 ± 12.8 cm and MUAC 28.2 ± 5.0 cm. According to BMI, undernutrition was 19.7%, normal status 37.9%, overweight 24.9%, obesity 17.5%. The concordance for undernutrition between BMI and MUAC was weak (kappa ¼ 0.3). In multinomial analysis, only no medication was negatively associated with undernutrition (OR ¼ 0.3). Obesity was positively associated with the urban environment (OR ¼ 4.8) and inactivity (OR ¼ 2.9) and negatively associated with male gender (OR ¼ 0.4), widowed (OR ¼ 0.2), head of household (OR ¼ 0.4), no income (OR ¼ 0.3), one pathology(OR ¼ 0.4), no medication (OR ¼ 0.2), having normal diastolic pressure (OR ¼ 0.2).Conclusions: Undernutrition and obesity (more frequent in women, and in urban area) affect 37.2% of the elderly. These nutritional disorders are a public health problem that cannot be ignored.

---

Fichiers liés : S2405457721003090.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Ludovic de GaboryPhilippe BoudardJean Pierre BessedeAline MaillardSabrina LacommeÉtienne GontierMarlene DurandJean-Christophe FricainAntoine BenardLaurence Bordenave
• Organismes : Bordeaux population health Bioingénierie tissulaire Bordeaux population health Bioingénierie tissulaire
• Publié dans Facial Plastic Surgery & Aesthetic Medicine le 17/08/2021

---

Résumé : Importance: A validated biomaterial would have several medical advantages in septorhinoplasties requiring a large-volume graft such as avoiding donor site morbidity, making ambulatory surgery possible, and reducing surgical costs. Objective: To assess the safety and efficacy of a ceramic to treat saddle and crooked noses. The main endpoint was the biocompatibility of the implant. The secondary endpoint was its functional and aesthetic efficacy. Design, Setting, and Participants: The nasal septum (NASEPT) study is a pilot multicenter noncomparative prospective phase IIa clinical trial. The biomaterial tested was a biphasic calcium phosphate implant composed of 75% hydroxyapatite and 25% beta tri calcium phosphate. This versatile material can be used to replace septal skeleton when it is absent or nonusable. We included 25 patients with a multifractured osseous and cartilaginous framework after several traumas or surgeries. The implant placement technique was identical to an extracorporeal septoplasty through the external approach. Main Outcomes and Measures: The primary endpoint was the occurrence of expected adverse and severe adverse events. The secondary endpoints were clinical functional and aesthetic results and histological microscopic modifications. Results: Any extrusion, infection, pain, and epistaxis were observed. All implants were placed in a sagittal, straight, and solid position without extralobular depression. Comparisons between pre- and postoperative symptoms showed that nasal comfort (p < 10(-4)) and quality of life (p < 10(-4)) were dramatically improved in all patients. The nasolabial angle (p = 0.047) and the columellar projection (p = 0.024) were improved after surgery. Histological data showed little submucosal inflammation at 6 months with well-differentiated epithelium. The mean follow-up was 23 months: three patients underwent revision surgery for functional or aesthetic details and four implants were removed (16%) owing to a foreign body reaction between 17 and 74 months. Conclusion and Relevance: The NASEPT implant meets functional and aesthetic requirements in complex septorhinoplasties but its long-term biocompatibility needs to be improved. It could potentially avoid donor site morbidity.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Michael SchermanJoanna BarrosRosa SantagataElodie LinPhilippe NicolasJean Pierre FaleniAxel Vincent-RandonnierPascal CherubiniFlorestan GuichardAjmal MohamedDaniel GaffieBrigitte Attal‐trétoutAlexandre Bresson
• Organismes : DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DMPE, ONERA, Université Paris Saclay [Palaiseau] DMPE, ONERA, Université Paris Saclay [Palaiseau] DMPE, ONERA, Université Paris Saclay [Palaiseau] DMPE, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau] DPHY, ONERA, Université Paris Saclay [Palaiseau]
• Publié dans Journal of Raman Spectroscopy le 26/10/2020

---

Résumé : The study of complex reactive flows met in aeronautical engines is an experimental challenge that requires the development of noninvasive and precise measurement techniques. Coherent anti-Stokes Raman scattering (CARS) is a standard spectroscopic technique used for temperature measurements, which provides unmatched reliability and accuracy at high repetition rate thanks to its recent adaptation to femtosecond temporal regime. This paper reports the first demonstration of hybrid fs/ps-CARS thermometry in a representative aeronautical combustor (ONERA MICADO test bench, Reynolds number ≈105). Single-shot N2 CARS spectra have been recorded at 1 kHz, allowing temperature follow up, statistical and frequency (0.1–500 Hz) analysis of CH4/air flame at 0.34-MPa total pressure. The achieved results demonstrate the ability of the technique to be applied in representative engines conditions and its maturity for semi-industrial applications.

---

Fichiers liés : DPHY21068_vacceptee.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2021
• Auteurs : Helena PereiraMohamed BouattourMarco BurgioEric AssenatJules GrégoryJean-Pierre BronowickiGilles ChatellierValérie VilgrainElisabeth Delhom-ChristolMarjolène FourcadeBoris GuiuAlina Diana IloncaJulie LonjonGeorges-Philippe PageauxMohamed Abdel-RehimWassim AllahamLaurent CasteraArnaud DieudonnéRachida LebtahiMaxime RonotAnnie SibertHélène ChorJulie DevictorHélène BarraudChristophe BazinLaetitia ImbertValérie LaurentElodie MathiasCarine Chagneau-DerrodeChristelle GallaisRémy PerdrisotChristine SilvainJean-Pierre TasuPatrick BorentainBardia FarmanRené GerolamiOlivier MundlerJean-Francois SeitzVincent VidalChristophe AubéFrancis BouchetAntoine BouvierOlivier CouturierFrédéric ObertiLaurent VervuerenIsabelle Brenot-RossiJulien DarreonJean Luc RaoulAnthony SarranJulia ChalayeCharlotte CostentinEmmanuel IttiHicham KobeiterAlain LucianiHélène MassetRené AdamMaïté LewinDidier SamuelJulien EdelineEtienne GarinSophie LaffontYan RollandIsabelle ArchambeaudThomas CarlierThomas EugeneEric FrampasC. CassinottoMartine GuyotJean-Baptiste HiriartBruno LapuyadeKarine TenderoJulien VergniolPhilippe BachellierJulien DétourBernard DuclosMichel GregetFrancois HabersetzerAlessio ImperialeElise EnderlinPhilippe MerleAgnès RodeJulie MorvanEric Nguyen-KhacAntoine TalbotThierry YzetGuillaume BaudinPatrick ChevallierAbakar MahamatFabien MaurelThierry PicheMicheline RazzoukPatrick HillonRomaric LoffroyMichel ToubeauJulie VincentJean-Marc VrigneaudGabriele BarabinoNadia BouariouaMuriel CuilleronMarie EcochardNathalie PrévotEvelyne RoussetVincent LeroyGhislaine RebouletJulie RouxChristian SengelValérie BourcierNathalie Ganne-CarrieOlivier SerorSylvie CostoThông DaoCédric DesmontsJean-Pierre PelageDidier DefezJérôme DumortierFrancesco GiammarilePierre-Jean ValetteMichela BernardiniNadia GhazarOlivier PellerinGilles ManceauPierre WeinmannAlexandra Heurgue-BerlotClaude MarcusDaniele SommacaleMaria-Angéla Castilla-LièvreAurélie ForbesSophie MaitreLysiane Marthey
• Organismes : CIC - HEGP Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génétique Moléculaire de Montpellier Hôpital Beaujon [AP-HP] Centre Hospitalier Régional Universitaire de Nancy CIC - HEGP Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Equipe IFTIM [ImViA - EA7535] Equipe IFTIM [ImViA - EA7535]
• Publié dans European Journal of Cancer le 22/10/2020

---

Fichiers liés : S0959804921003609.pdf

---

Source